PMID: 18210858Jan 24, 2008Paper

Preliminary trial of botulinum toxin A therapy for lower extremity spasticity in children with cerebral palsy

No to hattatsu. Brain and development
A NezuSaoko Takeshita

Abstract

Eleven children with gait disturbance due to cerebral palsy (mean age, 5.6 years, ranging from 2.4 to 11.5) were treated with Botulinum toxin A (BTA, BOTOX, Allergan) for improvement of spasticity and walking difficulty. BTA was injected into the gastrocnemius, adductors, and hamstring muscles with an initial total dose up to 8 units/kg or 100 units. Spasticity and gait disturbance were significantly improved in all patients 4 weeks after the treatment. Their parents also reported that BTA was helpful for brace tolerance and assistance of caregivers. No side effects including worsening of gait or signs of systemic adverse effects were observed. Management of leg spasticity with BTA is thought to be useful and safe, and approval for this use in Japan is recommended.

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Related Papers

Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association
Hilda Mulligan, Erin Wilmshurst
© 2021 Meta ULC. All rights reserved